Related Experiment Videos
Multiple-dose arecoline infusions in Alzheimer's disease
P N Tariot1, R M Cohen, J A Welkowitz
1Laboratory of Clinical Science, National Institute of Mental Health, Washington, DC.
Archives of General Psychiatry
|October 1, 1988
Summary
This study investigated arecoline hydrobromide
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease is a neurodegenerative disorder characterized by cognitive decline.
- Cholinergic system deficits are implicated in Alzheimer's disease pathophysiology.
Purpose of the Study:
- To evaluate the effects of central cholinergic stimulation using arecoline hydrobromide in patients with Alzheimer's disease.
- To assess dose-dependent cognitive, behavioral, and physiological responses.
Main Methods:
- Double-blind, randomized, placebo-controlled trial.
- Infusion of arecoline hydrobromide at 1, 2, and 4 mg/h for two hours.
- Assessment of cognitive function, psychomotor activity, affect, and neuroendocrine markers.
Main Results:
- Dose-dependent cholinergic stimulation confirmed by physiological and neuroendocrine effects.
- No significant improvement in most cognitive tasks, but marginal gains in picture recognition and word-finding.
- Lower doses improved psychomotor activation and affect; higher doses caused psychomotor retardation.
Conclusions:
- Central cholinergic modulation influences cognition, behavior, and affect in Alzheimer's disease.
- Patients with Alzheimer's disease exhibit unique behavioral sensitivity and dose-response patterns.
- Further research is warranted to explore cholinergic modulation in aging and Alzheimer's disease.